Zentalis Pharmaceuticals, Inc. · NASDAQ:ZNTL
Zentalis Pharmaceuticals — Investor Presentation (November 2026)
25 slides from Zentalis Pharmaceuticals's investor presentation, Nov 9, 2026
Slide 1: Pioneering WEE1 Inhibition to Deliver More Convenient, Targeted Cancer Care
Pioneering WEE1 Inhibition to Deliver More Convenient, Targeted Cancer Care Corporate Presentation | November 2026 Nasdaq: ZNTL
Slide 2: Forward-looking statements
Zentalis Pharmaceuticals, Inc. (“we,” “us,” “our,” “Zentalis” or the “Company”) cautions that this presentation (including oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All stat
Slide 3: A Focused Strategy to Address Critical Unmet Need in Ovarian Cancer and Beyond
A Focused Strategy to Address Critical Unmet Need in Ovarian Cancer and Beyond Initial focus to address ~20,000 Cyclin E1-positive PROC patients^, a poor prognostic biomarker population, with no specifically targeted treatment options Abbreviations: PROC = platinum-resistant ovarian cancer; ADC = an
Slide 4: A Focused Pipeline Prioritizing Cyclin E1-Positive PROC With Potential for Franchise Expansion
A Focused Pipeline Prioritizing Cyclin E1-Positive PROC With Potential for Franchise Expansion Abbreviations: PROC = platinum-resistant ovarian cancer; SOC = standard-of-care; 1L = first line; 2L = second line; PSOC = platinum-sensitive ovarian cancer; TNBC = triple-negative breast cancer * Also kno
Slide 5: ~50% of PROC Patients Are Cyclin E1-Positive With No Approved, Specifically Targeted Therapy
~50% of PROC Patients Are Cyclin E1-Positive With No Approved, Specifically Targeted Therapy 1. Cyclin E1-positive determined by an IHC assay and Zentalis proprietary cutoff; 3. 4. Abbvie Q4 2025 Earnings Cyclin E1 IHC+% based on literature and the unbiased CCNE1 amp & Cyclin E1 overlapping data gen
Slide 6: Robust Clinical Foundation Supports Azenosertib as Potential First-in-Class WEE1 Inhibitor
Robust Clinical Foundation Supports Azenosertib as Potential First-in-Class WEE1 Inhibitor for Cyclin E1-Positive PROC Abbreviations: PROC = platinum-resistant ovarian cancer; TRAEs = treatment-related adverse events; 5:2 schedule = 5 days once-daily administration of azenosertib, followed by 2 days
Slide 7: DENALI Phase 2: Integrated Topline Readout Expected in 1H 27
DENALI Phase 2: Integrated Topline Readout Expected in 1H 2027 Abbreviations: 5:2 schedule = 5 days once-daily administration of azenosertib, followed by 2 days without azenosertib; IHC= immunohistochemistry; MIRV=mirvetuximab soravtansine; PROC=platinum resistant ovarian cancer; DOR=duration of res
Slide 8: ASPENOVA Phase 3: Confirmatory Study in Cyclin E1-Positive PROC
ASPENOVA PHASE 3: Confirmatory Study in Cyclin E1-Positive PROC To Support Approvals in the U.S. and Major Ex-U.S. Markets Abbreviations: 5:2 schedule = 5 days once-daily administration of azenosertib, followed by 2 days without azenosertib; IHC= immunohistochemistry; MIRV=mirvetuximab soravtansine;
Slide 9: Cyclin E1-Positive PROC Patients Face Poor Prognosis with No Specifically Targeted Treatment Options
Cyclin E1-Positive PROC Patients Face Poor Prognosis with No Specifically Targeted Treatment Options Abbreviations: PROC = platinum-resistant ovarian cancer9
Slide 10: Cyclin E1 Protein Overexpression is the Key Biomarker Identifying PROC Patients
Cyclin E1 Protein Overexpression is the Key Biomarker Identifying PROC Patients Who May Benefit from Azenosertib Monotherapy Multiple mechanisms drive Cyclin E1 protein overexpression1, including: • CCNE1 gene amplification • Increased gene transcription • Reduced protein degradation *Cyclin E1 IHC+
Slide 11: Cyclin E1-Positive Patients Experience Significantly Worse Outcomes with Current Treatments
Cyclin E1-Positive Patients Experience Significantly Worse Outcomes with Current Approved Treatments Abbreviations: mPFS = median progression-free survival; DCR = disease control rate; mTTNT = median time to next treatment; OC = ovarian cancer; PROC = platinum-resistant ovarian cancer; Tx = treatmen
Slide 12: Standard-of-Care Single-Agent Chemotherapy Delivers Limited Benefits to PROC Patients
Standard-of-Care* Single-Agent Chemotherapy Delivers Limited Benefits to PROC Patients Direct cross-study comparison of results from independently conducted clinical trials is not intended on this slide. * Excludes recently approved taxane combo regimens Abbreviations: bev, bevacizumab; FR , folate
Slide 13: Azenosertib May Address Critical Gap in Cyclin E1-Positive PROC Treatment Landscape
Azenosertib May Address Critical Gap in Cyclin E1-Positive PROC Treatment Landscape* *If successful in clinical testing and approved by regulators Abbreviations: PROC = platinum-resistant ovarian cancer; FRα = Folate Receptor alpha 1 Excludes recently approved taxane combo regimens in the U.S. and s
Slide 14: Compelling Clinical Profile Across Multiple Studies Supports Registration Strategy
Compelling Clinical Profile Across Multiple Studies Supports Cyclin E1-Positive PROC Registration Strategy Abbreviations: PROC = platinum-resistant ovarian cancer 14
Slide 15: Azenosertib: A Differentiated, Potentially First-in-Class WEE1 Inhibitor
Azenosertib: A Differentiated, Potentially First-in-Class WEE1 Inhibitor 15 • Cyclin E1 overexpression increases CDK2 activity and accelerates G1-S transition, rendering cells more dependent on the DNA repair at the G2-M checkpoint • Inhibition of WEE1 activates CDKs, accelerates G1-S and G2-M trans
Slide 16: DENALI Part 1b Patient Characteristics: Heavily Pre-Treated PROC Population
DENALI Part 1b Patient Characteristics: Heavily Pre-Treated PROC Population Data cutoff: May 22, 2026. aFull Analysis Set: all treated patients. Biomarker dataset: all treated patients with evaluable tissue and Cyclin E1 IHC status. bHispanic. cOne patient had ECOG PS 2. dCCNE1 amplification defined
Slide 17: DENALI Part 1b Demonstrated Cyclin E1 as Predictive Biomarker for Response
DENALI Part 1b Demonstrated Cyclin E1 as Predictive Biomarker for Response to Azenosertib Data cutoff: May 22, 2026. aBiomarker dataset: all treated patients with evaluable tissue and Cyclin E1 IHC status. bIncludes patients who received at least one post-baseline scan. Horizontal lines at -30% and
Slide 18: Subsequent Anti-Cancer Therapies Were Similar in Cyclin E1-Positive and All Treated Patients
Subsequent Anti-Cancer Therapies Were Similar in Cyclin E1-Positive and All Treated Patients Data cutoff: May 22, 2026. Descriptive analysis; subsequent treatment was not randomized. Percentages are of patients in each analysis group. IHC, immunohistochemistry; PLD, pegylated liposomal doxorubicin.1
Slide 19: DENALI Part 1b Safety and Tolerability Summary
DENALI Part 1b Safety and Tolerability Summary Data cutoff: May 22, 2026; safety profile was consistent with prior reporting. bOne patient had sepsis and one patient had pancyenia. ALT, alanine aminotransferase; AST, aspartate aminotransferase; TRAE, treatment-related adverse event. aIf a patient ha
Slide 20: Building Azenosertib Franchise in Ovarian Cancer and Beyond
Building Azenosertib Franchise in Ovarian Cancer and Beyond 20
Slide 21: MUIR: Ongoing Phase 1b Study of Azenosertib in Combination with Bevacizumab
MUIR: Ongoing Phase 1b, Part 2 Study of Azenosertib in Combination with Bevacizumab Focused on Platinum Sensitive Ovarian Cancer Abbreviations: PROC = platinum-resistant ovarian cancer; 1L = first line; 2L = second line; PARPi = poly(ADP-ribose) polymerase inhibitor; ORR = overall response rate; DOR
Slide 22: Azenosertib Combinations Demonstrate Activity in Preclinical Triple-Negative Breast Cancer Models
Azenosertib Combinations Demonstrate Compelling Activity in Preclinical Triple-Negative Breast Cancer Models Preclinical data presented at AACR 2026 (Lee et al., Poster #3902, April 20, 2026) Abbreviations: TNBC = triple-negative breast cancer; ADC = antibody-drug conjugate; EV = enfortumab vedotin;
Slide 23: Pioneering WEE1 Inhibition to Deliver More Convenient, Targeted Cancer Care
23 Pioneering WEE1 Inhibition to Deliver More Convenient, Targeted Cancer Care for Patients with Cyclin E1-Positive Ovarian Cancer and Beyond
Slide 24: Our Mission: Delivering a More Convenient, Targeted Approach to Cancer Care
Our Mission: Delivering a More Convenient, Targeted Approach to Cancer Care * ** Cash, cash equivalents and marketable securities as of 9/30/26; Shares outstanding as of September 30, 2026 = 98.3M Abbreviations: PROC = platinum-resistant ovarian cancer; ADC = anti-body drug conjugate; OS = overall s
Slide 25: Contact
Julie Eastland Haibo Wang Chief Executive Officer jeastland@zentalis.com Chief Business Officer hwang@zentalis.com Aron Feingold VP, IR and Corporate Communications afeingold@zentalis.com
Zentalis Pharmaceuticals — Investor Presentation (November 2026) on 6ix